News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor for Wellvana’s $84 Million Capital RaiseMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for 89bio’s (Nasdaq:ETNB) Upsized $275 Million Follow-On OfferingMarch 2023
News | NewsSVB Securities Sets Record Straight on the Current and Previous Role of Chief Administrative Officer Joseph GentileMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Stagwell’s (NASDAQ: STGW) $108 Million Follow-On OfferingMarch 2023
News | NewsSVB Securities Continues its Independent Operations Unimpeded by Silicon Valley Bank’s Receivership ProceedingsMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Clearwater Analytics’ (NYSE: CWAN) $195 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Revolution Medicines’ (Nasdaq: RVMD) $300 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for 2seventy bio’s (Nasdaq: TSVT) Upsized $125 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Travere Therapeutics’ (Nasdaq: TVTX) $200 Million Follow-On OfferingMarch 2023
News | NewsSVB Securities Continues Build Out of Technology Investment Banking Platform with Addition of Scott SilverglateFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to Asceneuron on its Licensing Agreement with Ferrer for ASN90 for the Treatment of Progressive Supranuclear Palsy (PSP)February 2023
News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Abivax’s (Euronext Paris: ABVX) €130 Million Private PlacementFebruary 2023
